NXP 900
Alternative Names: eCF-506; NXP-900Latest Information Update: 25 Dec 2025
At a glance
- Originator University of Edinburgh
- Developer Nuvectis Pharma; University of Edinburgh
- Class Antineoplastics; Carbamates; Piperidines; Pyrazoles; Pyrimidines; Small molecules
- Mechanism of Action Proto-oncogene protein c-yes inhibitors; Src-family kinase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-small cell lung cancer; Solid tumours
- Preclinical Squamous cell cancer
Most Recent Events
- 17 Dec 2025 Phase-I clinical trials in Non-small cell lung cancer (Combination therapy) (PO)
- 27 Oct 2025 Drug-drug interaction data from a clinical trial in Healthy volunteers released by Nuvectis Pharma (700387549)
- 27 Oct 2025 Pharmacodynamics data from preclinical studies in Squamous cell cancer released by Nuvectis Pharma